Objective To observe whether Tongxinluo treatment delays progression of calcified aortic valve disease in the early stage. Methods One week after modeling, the mice were randomly divided into five groups: sham operation, model, Tongxinluo high-dose, Tongxinluo medium-dose and Tongxinluo low-dose groups. Changes in aortic valve peak velocity were assessed by Doppler ultrasound after Tongxinluo treatment for 6 weeks. The activity of serum myeloperoxidase (MPO) and the concentration of total cholesterol (TC) were measured. Pathological changes and calcium deposition were observed in the aortic valve. Infiltration of macrophages and differentiation of valve stromal cells into myofibroblasts and osteoblasts were examined by immunohistochemical staining. Results After 6 weeks of treatment, compared with the model group, Tongxinluo significantly reduced the peak flow velocity of the aortic valve (P<0.05), the serum level of total cholesterol, and the activity of serum MPO (P< 0.01). Compared with the Tongxinluo intervention group, the leaflet thickness of the aortic valve was significantly increased in the model group ( P< 0.05) and showed calcium salt deposition. Immunohistochemistry showed that, compared with the model group, macrophage recruitment was decreased, expression of α-SMA and OPN-positive cells were decreased in the Tongxinluo intervention group. Conclusions In the early stage of calcified aortic valve disease, Tongxinluo reduces oxidative stress by reducing the concentrations of serum TC, inhibiting infiltration of inflammatory macrophages, reducing MPO activity, and then affects the differentiation of valve stromal cells into myofibroblasts and osteoblasts to delay the progression of valvular calcification.